Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

4D Molecular Therapeutics (FDMT) Other Accumulated Expenses (2019 - 2025)

4D Molecular Therapeutics (FDMT) has disclosed Other Accumulated Expenses for 7 consecutive years, with $108000.0 as the latest value for Q3 2025.

  • On a quarterly basis, Other Accumulated Expenses fell 13.6% to $108000.0 in Q3 2025 year-over-year; TTM through Sep 2025 was $108000.0, a 13.6% decrease, with the full-year FY2024 number at $114000.0, up 9.62% from a year prior.
  • Other Accumulated Expenses was $108000.0 for Q3 2025 at 4D Molecular Therapeutics, up from $102000.0 in the prior quarter.
  • In the past five years, Other Accumulated Expenses ranged from a high of $1.8 million in Q4 2021 to a low of $45000.0 in Q1 2023.
  • A 5-year average of $293894.7 and a median of $161000.0 in 2025 define the central range for Other Accumulated Expenses.
  • Peak YoY movement for Other Accumulated Expenses: soared 260.49% in 2021, then tumbled 93.18% in 2023.
  • 4D Molecular Therapeutics' Other Accumulated Expenses stood at $1.8 million in 2021, then plummeted by 78.42% to $382000.0 in 2022, then tumbled by 72.77% to $104000.0 in 2023, then rose by 9.62% to $114000.0 in 2024, then decreased by 5.26% to $108000.0 in 2025.
  • Per Business Quant, the three most recent readings for FDMT's Other Accumulated Expenses are $108000.0 (Q3 2025), $102000.0 (Q2 2025), and $161000.0 (Q1 2025).